Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;9(3):254-65.
doi: 10.1007/s12015-012-9375-6.

Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms

Affiliations
Review

Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms

Timothy J Cashman et al. Stem Cell Rev Rep. 2013 Jun.

Abstract

Cell based treatments for myocardial infarction have demonstrated efficacy in the laboratory and in phase I clinical trials, but the understanding of such therapies remains incomplete. Mesenchymal stem cells (MSCs) are classically defined as maintaining the ability to generate mesenchyme-derived cell types, namely adipocytes, chondrocytes and osteocytes. Recent evidence suggests these cells may in fact harbor much greater potency than originally realized, as several groups have found that MSCs can form cardiac lineage cells in vitro. Additionally, experimental coculture of MSCs with cardiomyocytes appears to improve contractile function of the latter. Bolstered by such findings, several clinical trials have begun to test MSC transplantation for improving post-infarct cardiac function in human patients. The results of these trials have been mixed, underscoring the need to develop a deeper understanding of the underlying stem cell biology. To help synthesize the breadth of studies on the topic, this paper discusses current challenges in the field of MSC cellular therapies for cardiac repair, including methods of cell delivery and the identification of molecular markers that accurately specify the therapeutically relevant mesenchymal cell types. The various possible mechanisms of MSC mediated cardiac improvement, including somatic reprogramming, transdifferentiation, paracrine signaling, and direct electrophysiological coupling are also reviewed. Finally, we consider the traditional cell culture microenvironment, and the promise of cardiac tissue engineering to provide biomimetic in vitro model systems to more faithfully investigate MSC biology, helping to safely and effectively translate exciting discoveries in the laboratory to meaningful therapies in the clinic.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare no potential conflicts of interest

Figures

Figure 1
Figure 1
Schematic illustrating four primary mechanisms for mesenchymal stem cell (MSC)-based repair of injured myocardium. These include reprogramming of differentiated cardiomyocytes into cardiac progenitor cells, transdifferentiation of MSCs into cardiomyocytes, MSC secretion of paracrine factors, and direct electrophysiological coupling of MSCs with host myocardium.

References

    1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. - PubMed
    1. Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. The FASEB Journal. 2004;18:980–982. - PubMed
    1. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–49. - PubMed
    1. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. 2009;54:2277–2286. - PMC - PubMed
    1. Li Y, Yao Y, Sheng Z, Yang Y, Ma G. Dual-modal tracking of transplanted mesenchymal stem cells after myocardial infarction. International Journal of Nanomedicine. 2011;6:815–823. - PMC - PubMed

Publication types